Compare AbbVie Inc (ABBV) vs Schwab US Large Cap Growth ETF (SCHG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Schwab US Large Cap Growth ETF — how do they compare? AbbVie Inc trades at $253.44 (market cap $449.91B), while Schwab US Large Cap Growth ETF trades at $34.21. The key difference: AbbVie Inc pays a 2.72% dividend while Schwab US Large Cap Growth ETF pays none. Which is the better fit depends on your goals.
| ABBV | SCHG | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Sector/Thematic |
52-Week High | $261.07 | $35.30 |
52-Week Low | $184.85 | $28.10 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $253.61, down 0.45% on the day, with strong technical momentum showing bullish moving averages and key support at $253. The company reported Q1 2026 EPS of $2.65, beating expectations, while revenue growth is supported by Skyrizi and Rinvoq offsetting Humira declines. Analysts maintain a bullish consensus with 68% buy ratings and a $266.33 price target, representing 5% upside potential.
The outlook remains positive with robust immunology portfolio performance and dividend growth, though risks include patent cliffs in the 2030s and competitive pressures. Current valuation metrics appear elevated with P/E at 124.83, requiring sustained earnings growth to justify premium multiples. The stock offers income appeal with consistent dividend payments while navigating portfolio transition.
SCHG, the Schwab U.S. Large-Cap Growth ETF, trades at $34.53, up 1.2% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF provides concentrated exposure to large-cap growth stocks, particularly in technology, with top holdings like Nvidia, Apple, and Microsoft. Recent news highlights its positioning to benefit from AI-driven capital expenditure growth, though some analysts note concentration risks.
The outlook for SCHG is supported by strong AI adoption trends and institutional inflows, but risks include high portfolio concentration and sensitivity to interest rate changes. Valuation remains elevated, with a portfolio P/E around 32x, which could pressure returns if growth expectations moderate. Investors should weigh the growth potential against these concentration and macroeconomic risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →
